TLDR: UK-based CHARM Therapeutics has successfully closed an oversubscribed Series B funding round, raising $80 million. The capital will be used to propel its AI-enabled menin inhibitor, designed for Acute Myeloid Leukemia (AML), into clinical development. The company’s innovative DragonFold AI platform has been instrumental in developing a drug candidate that demonstrates efficacy against resistance mutations and robust tumor regression in preclinical studies.
London, UK – September 2, 2025 – CHARM Therapeutics, a pioneering UK-based biotechnology company specializing in precision oncology, today announced the successful closure of an oversubscribed Series B funding round, securing an impressive $80 million. This significant investment is earmarked to accelerate the clinical development of its next-generation menin inhibitor, a promising therapeutic candidate for Acute Myeloid Leukemia (AML).
The funding round was co-led by prominent investors NEA and SR One, with substantial participation from OrbiMed, F-Prime Capital, Khosla Ventures, and NVIDIA. This diverse group of investors underscores the strong confidence in CHARM Therapeutics’ innovative approach to drug discovery and its potential to address critical unmet needs in cancer treatment.
At the heart of CHARM Therapeutics’ breakthrough is its proprietary DragonFold AI platform. This advanced artificial intelligence technology has been pivotal in the development of their lead drug candidate. Preclinical studies have demonstrated the candidate’s remarkable ability to remain effective against all known resistance mutations, a common challenge in AML treatment. Furthermore, the drug has shown robust tumor regression in these models, coupled with favorable safety and dosing profiles, paving the way for its progression into human clinical trials.
Speaking on the achievement, a representative from CHARM Therapeutics highlighted the transformative potential of their AI-driven platform. ‘The successful completion of this Series B round is a testament to the power of our DragonFold AI platform and the dedication of our scientific team,’ the representative stated. ‘This capital infusion will enable us to push our lead AML program into the clinic, bringing us closer to delivering a much-needed, effective treatment option for patients battling this aggressive form of leukemia.’
Also Read:
- Predoc Secures $30 Million to Revolutionize Healthcare Data Management with AI-Powered Automation
- Ketryx Secures $39 Million Series B to Advance AI-Powered Compliance in Life Sciences
With this latest funding, CHARM Therapeutics has now raised over $150 million to date, solidifying its position as a significant player in the AI-enabled drug discovery landscape. The company’s focus on precision oncology, combined with its cutting-edge AI capabilities, positions it at the forefront of developing novel therapies that could revolutionize cancer care.
